PDF(Pubmed)
Abstract：
Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles published in the English language were searched in PubMed, Google Scholar, and Google. Keywords used for the search were: lipodystrophy, lipodystrophy and HIV, ART and lipodystrophy, HIV treatment, metabolic syndrome and HIV. Articles with full abstract information were read for those that met the objective criteria of the review, then full text of the articles was accessed and used. It was revealed by the literature that patients who developed lipodystrophy are characterized by insulin abnormality, obesity, diabetes mellitus, dyslipidemia, fatty liver disease, and ovarian dysfunction. Anthropometric measurements have been known to change significantly with lipodystrophy. HIV patients suffering from hepatitis C virus, hepatitis B virus, who take a protease inhibitor, are changing treatment or duration of treatment, and are women are the common risk factors for lipodystrophy. The metabolic syndrome seen in HIV patients associated with lipodystrophy can further be complicated to different adverse health effects and can result in increased morbidity and mortality rate if not treated. Existing studies have successfully identified several challenges faced by HIV AIDS patients due to lipodystrophy, including low self-esteem, compromised quality of life, and poor treatment adherence. However, it is crucial to acknowledge that there may be numerous other challenges that have yet to be discovered, emphasizing the need for further studies. It is recommended that managing dyslipidemia, treating diabetes mellitus, modifying lifestyle, and improving the anthropometric measurements have crucial roles to halt further complications associated with lipodystrophy.
摘要：
脂肪营养不良综合征是一种医学病症,其特征在于缺乏脂肪组织而没有任何潜在的饥饿或大分子分解。在艾滋病患者中，使用高活性抗逆转录病毒疗法（HAART）可导致获得性脂肪营养不良，艾滋病毒/艾滋病患者的患病率为10％至83％。旨在回顾当前对AIDS患者与脂肪营养不良相关的生物学描述和挑战的理解。在PubMed中搜索了以英语发表的相关文章，谷歌学者，和Google。用于搜索的关键词是：脂肪营养不良，脂肪营养不良和艾滋病毒，ART和脂肪营养不良，艾滋病毒治疗，代谢综合征和HIV。对于符合审查客观标准的文章，阅读了具有完整摘要信息的文章，然后文章的全文被访问和使用。文献表明，发生脂肪营养不良的患者以胰岛素异常为特征，肥胖，糖尿病,血脂异常,脂肪肝,和卵巢功能障碍。已知人体测量随着脂肪营养不良而显着改变。患有丙型肝炎病毒的HIV患者，乙型肝炎病毒，服用蛋白酶抑制剂的人，正在改变治疗或治疗持续时间，女性是脂肪营养不良的常见危险因素。在与脂肪营养不良相关的HIV患者中看到的代谢综合征可以进一步复杂化不同的不良健康影响,并且如果不治疗,可以导致增加的发病率和死亡率。现有的研究已经成功地确定了艾滋病患者由于脂肪营养不良而面临的几个挑战，包括低自尊,生活质量受损，治疗依从性差。然而,至关重要的是要承认可能还有许多其他挑战有待发现，强调需要进一步研究。建议管理血脂异常，治疗糖尿病，改变生活方式,改善人体测量学测量对于阻止与脂肪营养不良相关的进一步并发症具有关键作用。
